Drug development has undergone significant changes in recent years, particularly in the design and conduct of early phase (Phase 1/2a) non-oncology clinical studies. The goal of these changes has been to accelerate the early clinical drug development process, ensure safer decision-making, and deliver potential new medicines to patients sooner. In this white paper, we explore the factors that have driven these changes, analyze their impact on the design and execution of these studies, and examine the challenges that clinical researchers are facing.
Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
